Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenues:
Total revenues	$ 9,191	$ 8,243	$ 17,211	$ 10,772
Operating expenses:
Cost of revenues	(4,455)	(3,621)	(7,816)	(3,683)
Research and development expenses	(4,088)	(3,150)	(7,605)	(7,018)
Selling, general and administrative expenses	(11,047)	(12,854)	(23,747)	(24,901)
Total operating expenses	(19,590)	(19,625)	(39,168)	(35,602)
Loss from operations	(10,399)	(11,382)	(21,957)	(24,830)
Other income (expense):
Other income (expense), net	(92)	470	216	348
Interest expense, net	(198)	(236)	(413)	(457)
Loss before income taxes	(10,689)	(11,148)	(22,154)	(24,939)
Income tax expense	(385)	(606)	(739)	(796)
Net loss	$ (11,074)	$ (11,754)	$ (22,893)	$ (25,735)
Loss per share
Basic loss ($ per share)	$ (0.18)	$ (0.29)	$ (0.38)	$ (0.77)
Diluted loss ($ per share)	$ (0.18)	$ (0.29)	$ (0.38)	$ (0.77)
Weighted average number of shares:
Basic (in shares)	63,238,080	40,573,848	61,028,388	33,532,837
Diluted (in shares)	63,238,080	40,573,848	61,028,388	33,532,837
Product revenue, net
Revenues:
Total revenues	$ 8,680	$ 6,940	$ 15,720	$ 7,070
Collaboration revenue
Revenues:
Total revenues	96	813	725	2,815
Research premium and grant revenue
Revenues:
Total revenues	$ 415	$ 490	$ 766	$ 887